← All organizations
Highest phase reached
Phase 4
First clinical trial
Dec 1, 2003First marketed drug
May 19, 2023First NDA
May 19, 2023Last known activity
Jan 31, 2026
Timeline
1990s
- Jan 1, 1999
Genmab— Founded
2020s
- May 19, 2023
Epcoritamab— Marketing Organization
- May 19, 2023
Epcoritamab— NDA Organization
- May 19, 2023
Epcoritamab— NDA Secondary Org
- Apr 3, 2024
ProfoundBio US Co.— Acquired
- Oct 1, 2025
Merus Labs— Acquired
Drugs by trial phase (63 distinct, 93 trials)
Phase 4 (1 own, 0 via acquisition)
Phase 3 (21 own, 4 via acquisition)
Phase 2 (23 own, 8 via acquisition)
Phase 1 (4 own, 2 via acquisition)
Indications
Studied for
- Carcinoma
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Carcinoma, Renal Cell
- Carcinoma, Squamous Cell
- Carcinoma, Transitional Cell
- Colorectal Neoplasms
- Endometrial Neoplasms
- Esophageal Neoplasms
- Fallopian Tube Neoplasms
- Head and Neck Neoplasms
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Lung Neoplasms
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Mantle-Cell
- Lymphoma, Non-Hodgkin
- Lymphoma, T-Cell
- Neoplasms
- Neoplasms, Squamous Cell
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Prostatic Neoplasms
- Squamous Cell Carcinoma of Head and Neck
- Thyroid Neoplasms
- Triple Negative Breast Neoplasms
- Urinary Bladder Neoplasms
- Uterine Cervical Neoplasms
- Uterine Neoplasms
Marketed drugs (1)
Subsidiaries (2 direct, 2 total across the full acquisition tree)
Recent trials (50)
- NCT05692050CollaboratorN/A—
- NCT05733650Lead sponsorN/A—
- NCT07288177OfficialPhase 2Jan 31, 2026
- NCT07288177Lead sponsorPhase 2Jan 31, 2026
- NCT07225270Lead sponsorPhase 3Jan 15, 2026
- NCT07225270OfficialPhase 3Jan 15, 2026
- NCT06919939CollaboratorPhase 2Dec 1, 2025
- NCT07166094Lead sponsorPhase 3Nov 21, 2025
- NCT07166094OfficialPhase 3Nov 21, 2025
- NCT07030699CollaboratorPhase 2Aug 13, 2025
- NCT07108998CollaboratorPhase 2Aug 1, 2025
- NCT06984328Lead sponsorPhase 2Jul 25, 2025
- NCT06984328OfficialPhase 2Jul 25, 2025
- NCT07079631CollaboratorPhase 1/Phase 2Jul 18, 2025
- NCT06811272CollaboratorPhase 2Jul 16, 2025
Details
- Founded
- Copenhagen, DK Jan 1, 1999
- First NDA
- May 19, 2023
- Last known activity
- Jan 31, 2026
Designations held
- Orphan drug
- Priority review
- Accelerated approval